Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer.
<h4>Background</h4>There was no clear evidence whether the initial dose of enzalutamide affects the incidence of adverse events (AEs), and oncological outcome in patients with castration-resistant prostate cancer (CRPC).<h4>Methods</h4>The clinical charts of 233 patients with...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/b374a1b5ca054b888c6dc81210d59f89 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|